Company profile: Aegera Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage targeted therapeutics addressing major unmet medical needs, with three programs in clinical development—two in oncology and one in neuropathic pain—and ongoing identification of novel development candidates based on core technologies. Part of Pharmascience Inc.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aegera Therapeutics
Rain Oncology
HQ: United States
Website
- Description: Provider of precision oncology therapies targeting oncogenic drivers, developing milademetan, an oral small molecule inhibitor of the p53-MDM2 complex for various cancers. Clinical programs include MANTRA (Phase 3 in dedifferentiated liposarcoma), MANTRA-2 (Phase 2 in TP53 wildtype/MDM2-amplified solid tumors), and MANTRA-4 (Phase 1/2 with atezolizumab in CDKN2A loss, TP53 wildtype tumors).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rain Oncology company profile →
Molecular Insight
HQ: United States
Website
- Description: Provider of biopharmaceutical innovations in molecular medicine, applying molecular-level disease identification and targeting to improve patient healthcare and address significant unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Insight company profile →
Proteomedix
HQ: Switzerland
Website
- Description: Provider of blood-based prostate cancer diagnostics, notably Proclarix: a test panel that integrates biomarkers and patient data to compute a risk score for high-grade prostate cancer using samples taken for PSA testing. Clinical evidence from 955 subjects shows Proclarix reduces unnecessary biopsies by accurately detecting clinically significant cancer; offers biomarker signatures for diagnosis, prognosis, and therapy management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proteomedix company profile →
Delphinus Medical
HQ: United States
Website
- Description: Provider of breast cancer screening solutions for hospitals and imaging clinics, developing, commercializing, and servicing the SoftVue 3D Whole Breast Ultrasound Tomography, a 3D whole breast ultrasound system for dense breast screening that increases cancer detection by 20% when used alongside mammography.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delphinus Medical company profile →
Epsilogen
HQ: United Kingdom
Website
- Description: Provider of immuno-oncology therapies developing immunoglobulin antibodies for cancer, focusing on IgE-based drugs for solid tumors. Offerings include MOv18 IgE, targeting folate receptor alpha for ovarian cancer with Phase I safety and early clinical activity, and an IgEG fusion platform combining IgE and IgG to enhance potency and serum half-life, with in vitro and in vivo proof of concept.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epsilogen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aegera Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aegera Therapeutics
2.2 - Growth funds investing in similar companies to Aegera Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aegera Therapeutics
4.2 - Public trading comparable groups for Aegera Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →